

**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1. (previously presented) A glycoconjugate formed by non-covalent association of a polysaccharide with a polypeptide, wherein the polysaccharide has a molecular weight between 50 and 250 KDa, supporting phosphate functional groups in range 1 of these phosphate groups by between 5 and 25 residues of monosaccharide, with 40% mannose and 60% of either (1) glucose, (2) galactose, or (3) glucose and galactose making up a main skeleton integrated by 1-6 bonds with 1-2 branches; wherein the polypeptide comprises a consensus amino-acid sequence (SEQ ID NO:1) determined by  $Z_{3-48}CZ_{9-13}C(Q,E,R,K) Z(Z_{\text{hydrophobic}}) (L,I,V,M)Z_{15-39}CC(Z_{\text{hydrophilic}}) (Q,E,H) (L,V)Z_6 CZC Z_2(L,I)Z_{13-56}G Z_{15-26} CZ(V,I,L,M)Z_{1-8} CZ_{1-12}$ , where the parentheses in the sequence indicate a preferential order, and wherein  $Z_n$  is selected from the group consisting of n-amino acids.

Claim 2. (previously presented) A glycoconjugate as claimed in 1, wherein the polypeptide comprises one or two polypeptides, wherein a mol/mol relation between the two polypeptides is between 1/3 and 3/1.

Claim 3. (amended twice) A glycoconjugate as claimed in Claim 1, wherein the polypeptide is a dimer having a molecular weight of  $12 \pm 0.5$  KDa, wherein the dimer has a minor subunit and a major subunit,

wherein the minor subunit is

ESKGEREGSSSQQCRQEVQRKDLSSCERYLRQSSRR (SEQ ID NO:2) or

PSQQGCRGQIQEQQLNRQCQEYIKQQVSGQGPRR (SEQ ID NO:4) and wherein the

major subunit is

QQQESQQLQQCCNQVKQVRDECQCEAIKYIAEDQIQGQLHGEESERVAQRAGEIVSSCGVRCMRQ

TR (SEQ ID NO:3) or

QERSLRGCCDHLKQMOSQCRCEGLRQAIEQQQSQGLQGDVFEAFRTAANLPSMCGVSPTECRF

(SEQ ID NO:5);

wherein specific amino acids of the consensus sequence are indicated by boldface.

Claim 4. (previously presented) A glycoconjugate as claimed in Claim 1, wherein the polypeptide is stabilized by disulphur or dimethylene bridges, and can be oligomeric or dimeric.

Claim 5. (previously presented) A glycoconjugate as claimed in Claim 1 wherein the glycoconjugate has pharmacological activity and can be used medically to treat disorders of an immunological system related to a higher production of tumor necrosis factor (TNF).

Claim 6. (previously presented) A glycoconjugate as claimed in Claim 1 wherein the glycoconjugate can be used in pharmacy to prepare galenical forms.

Claim 7. (currently amended) A glycoconjugate as claimed in Claim 1 wherein the polypeptide has at least two disulphur or two dimethylene intercatenary bridges.

Claim 8. (previously presented) A glycoconjugate as claimed in Claim 3, wherein the glycoconjugate has pharmacological activity and can be used medically to treat disorders of an immunological system related to a higher production of tumor necrosis factor (TNF).

Claim 9. (previously presented) A glycoconjugate as claimed in Claim 1, wherein the glycoconjugate has pharmacological activity and can be used medically to inhibit production of tumor necrosis factor (TNF).

Claim 10. (previously presented) A glycoconjugate as claimed in Claim 3, wherein the glycoconjugate has pharmacological activity and can be used medically to inhibit production of tumor necrosis factor (TNF).